Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says

MT Newswires Live2025-03-31

Teva Pharmaceutical's (TEVA) cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.

The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS "which makes us believe there is no margin expansion priced-in at these levels."

However, the company's management is confident it can grow its EBITDA through "strong topline growth and cost optimization," the note said.

UBS said the "Revlimid LOE will have a greater impact than what we previously anticipated," however, on Teva's Q1 call it will "look for detailed cost optimization plan to address this impact."

UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.

Price: 15.37, Change: +0.29, Percent Change: +1.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523924601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523924601","market":"us","top_or_hot":-1,"title":"Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical's (TEVA) cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.</p><p>The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS \"which makes us believe there is no margin expansion priced-in at these levels.\"</p><p>However, the company's management is confident it can grow its EBITDA through \"strong topline growth and cost optimization,\" the note said.</p><p>UBS said the \"Revlimid LOE will have a greater impact than what we previously anticipated,\" however, on Teva's Q1 call it will \"look for detailed cost optimization plan to address this impact.\"</p><p>UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.</p><p>Price: 15.37, Change: +0.29, Percent Change: +1.89</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical's (TEVA) cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.</p><p>The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS \"which makes us believe there is no margin expansion priced-in at these levels.\"</p><p>However, the company's management is confident it can grow its EBITDA through \"strong topline growth and cost optimization,\" the note said.</p><p>UBS said the \"Revlimid LOE will have a greater impact than what we previously anticipated,\" however, on Teva's Q1 call it will \"look for detailed cost optimization plan to address this impact.\"</p><p>UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.</p><p>Price: 15.37, Change: +0.29, Percent Change: +1.89</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523924601","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523924601","pubTimestamp":1743436480,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical's  cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS \"which makes us believe there is no margin expansion priced-in at these levels.\"However, the company's management is confident it can grow its EBITDA through \"strong topline growth and cost optimization,\" the note said.UBS said the \"Revlimid LOE will have a greater impact than what we previously anticipated,\" however, on Teva's Q1 call it will \"look for detailed cost optimization plan to address this impact.\"UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.Price: 15.37, Change: +0.29, Percent Change: +1.89","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4596":"哈里斯概念","BK4007":"制药","BK4559":"巴菲特持仓","TEVA":"梯瓦制药","BK4584":"避孕概念","BK4566":"资本集团","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"瑞银表示，梯瓦制药即将推出的成本优化计划可能会带来显着好处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical's (TEVA) cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS \"which makes us believe there is no margin expansion priced-in at these levels.\"However, the company's management is confident it can grow its EBITDA through \"strong topline growth and cost optimization,\" the note said.UBS said the \"Revlimid LOE will have a greater impact than what we previously anticipated,\" however, on Teva's Q1 call it will \"look for detailed cost optimization plan to address this impact.\"UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.Price: 15.37, Change: +0.29, Percent Change: +1.89","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523924601","isCrawlerRequest":true}